Background: Now-a-days, the model of "hybrid drugs" has acquired recognition in medicine due to their significant role in the treatment of different health problems.
INTRODUCTION
Hybrid molecules are designed by chemical hybridization wherein two drug pharmacophores are incorporated in a single molecule with an objective to put forth twin drug action [1] . For example, one of the pharmacophores possibly will target explicitly tumor vessels, whereas another may be the active agent [2] . Hence, hybrid molecules are also known as multifunctional or conjugated drugs. Hybrid molecules may also exhibit synergetic effect compared to the individual pharmacophores [3] .
Natural products and their derivatives have been widely used in cancer chemotherapy as Microtubule-Binding Agents (MBA) [4] [5] [6] . There are two classes of MBAs. Either they stabilize microtubules to promote polymerization or destabilize the microtubules to promote depolymerization [7] [8] [9] [10] . Both types interfere with the mitotic spindle assembly during cell division, resulting in cell death. Studies have shown that most MBAs have anti vascular effects from antiangiogenetic or vascular disrupting activities, or both [11 It was reported that substituted triazoles, oxadiazoles including 3,4-disubstituted-1,2,5-oxadiazole (combretafurazan) [20] and 2,5-disubstituted-l,3,4-oxadiazole [21] (3 and 4) are more potent than combretastatin itself. A key structural factor for tubulin affinity is the presence of the double bond or a suitable linker, forcing the two aromatic rings to stay within an appropriate distance. To overcome the problem of the isomerization of the active cis double bond into an inactive trans form, heterocyclic rings were used in place of the ethene bridge. The synthesis and biological activities of a series of CA-4 analogues with a five-membered heterocycles include isoxazole as linker of the two aromatic rings of CA-4 (5 and 6) have been reported [22] .
Combretastatin A-4 (CA-4) analogs exhibiting comparable activity have been developed to avoid problem of isomerization of cis double bond [23] . There is always an equal effort to make a more active drug than combretastatin A-4, and to achieve this heterocyclic ring was placed in between the two aromatic rings with retaining activity. Survey of literature reveals that, a variety of chalcones exhibited potent cytotoxicity activities against human cancer cell lines [24, 25] . So by keeping in mind about the advantages of linking of CA-4 with heterocyclic rings and the chalcones for usage as anticancer agents, we have designed and synthesized a series of isoxazole-chalcones which contain structural features of combretastatin A-4 and chalcones. These conjugates have not been reported so far to the best of our knowledge, where we can expect these molecules as potent inhibitors of tubulin polymerization [26] .
EXPERIMENTAL SECTION
All the reactants, reagents and solvents were obtained from commercial sources and were of analytical grade. Melting points were determined in open glass capillaries on a Fisher-Johns melting point apparatus and are uncorrected. ELEMENTAR/Vario EL Cube was used to carry out elemental analysis. NMR ( 1 H 400 MHz; 13 C 100 MHz) were recorded at room temperature in CDCl 3 as solvent and TMS as an internal standard (δ = 0 ppm), and the values were reported in the following order: Chemical shift (δ in ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet,= quartet of quartet, brs= broad singlet) coupling constants (J in Hz), and integration. Mass spectra were recorded on a VG micromass70-70H instrument. All the reactions were monitored by Thin Layer Chromatography (TLC) on precoated silica gel GF-254 (100-200 mesh); spots were visualized under UV light at 254 nm. A mixture of l-(3,4,5-trimethoxyphenyl)ethanones (13a) (210 mg, 1 mmol) and 5-(3,4,5-trimethoxyphenyl)isoxazole-3-carbaldehyde (12a) (263 mg, 1 mmol) was dissolved in 10 mL ethanol. To this mixture, sodium hydroxide (40%, 1 mL) was added at 0-5 o C. The reaction mixture was stirred at room temperature for 2 h. Then this reaction mixture was poured over crushed ice and acidified with dilute hydrochloric acid. Following the same procedure as depicted for 14a, the other isoxazole-chalcone derivatives 14b-m were prepared. (E)-3-(5-(3,4-Dimethoxyphenyl)isoxazol-3-yl)-l-(4-fluorophenyl) prop-2-en-l-one (14h) 
(E)-1-(3,4-Dimethoxyphenyl)-3-(5-(4-methoxyphenyl) isoxazol-3-yl)prop-2-en-l-one (14j)
Yellow solid, Yield: 78%;MR: 163-165°C; DIPMS: m/z=365.12; Elemental analysis: Calculated (%) for C 21 
(E)-l-(4-Methoxyphenyl)-3-(5-(4-methoxyphenyl) isoxazol-3-yl) prop-2-en-1-one (14k)

(E)-1-(4-Fluorophenyl)-3-(5-(4-methoxyphenyl) isoxazol-3-yl) prop-2-en-l-one (141)
SRB Assay
In the present study, SRB assay was performed as per protocol of Skehan et al. [29, 30] . Sulforhodamine B (0.4% w/v) solution was prepared in 1% acetic acid solution. 70 µl Sulforhodamine B solution was transferred to each well and allowed for twenty minutes at room temperature. Dilute acetic acid (1%) was used to wash the plates for five times after the removal of SRB and air dried. Unbuffered tris-base solution (200 ml of 10 mM) was used to solubilise the bound SRB while leaving the plates for about 10 min on a plate shaker. Absorbance in a 96-well plate reader (Anthos-2001, Anthos Labteck Instruments, A-5022, Salzburg) was measured at 492 nm by subtraction of background readings measured at 620 nm. Statistical analysis (coefficient of variation and mean values of six replicate wells) was carried out using Excel 7.0 software.
In Vitro Cytotoxicity Assay
Exponential growth of cells was initiated at 37 o C for 24 hours by inoculating 100 µl per cell i.e., 10,000 cells /well. Two microplates were used for each cell line and twice repeated the experiments. Complete culture medium was used to dilute after 24 h. For each concentration of synthesized compound, six replicate wells were used. SRB assay was used to evaluate the cytotoxicity after 24h. Regression analysis was used on dose-response curves to estimate IC 50 values (50% inhibitory concentration) [29] .
RESULTS AND DISCUSSIONS
Chemistry
The synthesis of isoxazole-chalcone (14a-m) derivatives is sketched in Scheme 1, in which the derivatives were obtained by the Claisen-Schmidt condensation of suitable substituted acetophenones with isoxazole aldehydes. The key intermediates 5-substituted phenyl-isoxazol-3-carbaldehydes were prepared in four sequential steps. Initially substituted acetophenones (7a-d) reacted with diethyl oxalate (8) in the presence of sodium ethanoate in ethanol to obtain ethyl 2,4-dioxo-4-(substituted phenyl) butanoates (9a-d) . This was further cyclized with hydroxylamine hydrochloride in ethanol to produce ethyl 5-substituted phenyl-isoxazol-3-carboxylates in good yields. The obtained carboxylates were reduced to (5-substitutedphenyl-isoxazol-3-yl) methanol with LiAlH 4 in THF. These were selectively oxidized to 5-substituted phenyl-isoxazol-3-carbaldehydes by IBX (2-iodoxy benzoic acid) in DMSO. The obtained carbaldehydes were condensed with 1-(3, 4, 5-trimethoxyphenyl) ethanone (13a-d) in presence of 10% aqueous sodium hydroxide solution to form a compound 14a-m.
In Vitro Cytotoxic Studies
These synthesized isoxazole-chalcone compounds (14a-m) were evaluated for their anticancer activity in selected human cancer cell lines like DU145 (prostate carcinoma), MDA MB-231, MCF-7 (breast cancer) and A549 (non-small cell lung cancer) cell lines ( Table 1 ) by using sulforhodamine B (SRB) method [27, 28] and shown in IC 50 values. IC 50 means that the concentration at which minimum 50% of the cancer cell lines shall be destroyed The trimethoxy chalcone (TMC) was used as positive control for screening of anticancer activities [30] [31] [32] and TMC derivatives are also exhibited potent anticancer activities against different human cancer cell lines [33] [34] [35] . The synthesized compounds exhibited anticancer potency with IC 50 values ranging from 0.96 to 26.29 µM. Interestingly, almost all these new compounds showed significant activity towards DU-145 cancer cell line compared to other cell lines. According to structure-activity relationship studies, the presence of electron donating groups like methoxy, dimethoxy or trimethoxy substituents on either of phenyl rings showed enhanced anti-cancer activities especially on DU-145 and MDA-MB-231 cancer cell lines. The present observations are in similar lines to previous reports by other researchers in which the presence of 3,4,5-trimethoxyphenyl group in chalcones was ascribed to their exhibited anticancer activity [31] .
Among the 13 series of the compounds, the compounds 14i and 14j exhibited potent cytotoxic activities against DU-145 prostate cancer cell line with IC 50 values of 0.96 µM and 1.06 µM as compared to the positive control (IC 50 value 4.10 µM). So these two compounds may be identified as promising drug lead compounds. The compounds 14a, 14b, 14c, 14d, 14e and 14k showed promising cytotoxic activities against DU145 cell line with IC 50 values of 1.80 µM, 1.72 µM, 2.32 µM, 2.32 µM, 1.23 µM and 1.93 µM respectively. While the compounds, 14c, 14e and 14i showed good cytotoxic activities against MDA-MB-231 cell line with IC 50 Scheme 1. Synthesis of novel hybrid isoxazole chalcone derivatives (14a-m). 
CONCLUSION
In the present study, we have synthesized new series of isoxazole-chalcone conjugates (14a-m) and evaluated them for their in vitro cytotoxic activity. It was observed that compounds -14a, 14b, 14e, 14i, 14j and 14k exhibited potent cytotoxic activity against prostate DU-145 cancer cell line. The observed cytotoxic studies were related to the presence of electron donating groups like methoxy, dimethoxy or trimethoxy substituents (especially 3,4,5-trimethoxyphenyl group) on either of phenyl rings.
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